A new study seeking to shed light on real-world COVID-19 vaccine effectiveness shows a widening gap between Moderna’s and Pfizer’s vaccines four months after each vaccine’s second dose. Among the 3,600-plus U.S. adults without immunocompromising conditions who were enrolled in the study, vaccine effectiveness against COVID-19 hospitalization within the first four months of being fully inoculated was higher for the Moderna vaccine (93 percent) than the Pfizer–BioNTech vaccine (88 percent) and the Johnson & Johnson vaccine (71 percent), according to the Centers for Disease Control and Prevention (CDC). While the Moderna vaccine’s effectiveness dropped slightly to 92 percent after 120 days of full vaccination (with a median of 141 days), Pfizer’s declined significantly to 77 percent (with a median of 143 days), researchers found. Because only a limited number of patients received the J&J shot more than 120 days before the onset of illness, its effectiveness wasn’t stratified by time …